other material
confidence high
sentiment positive
materiality 0.80
CEL-SCI presents Multikine data: 5yr survival 73% vs 45% control; risk of death halved
CEL SCI CORP
- Multikine cut risk of death by 50% in low PD-L1 head and neck cancer patients: 73% survival vs 45% control at 5 years.
- Hazard ratio 0.35 (95% CI 0.19-0.66, log rank p=0.0015).
- Multikine targets low PD-L1 tumor expression, contrasting with checkpoint inhibitors like Keytruda.
- Company working to commence FDA confirmatory Registration Study for Multikine.